RecruitingNCT05062421

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Enrollment

540 participants

Start Date

Apr 1, 2021

Study Type

OBSERVATIONAL

Conditions

Arthritis, Rheumatoid

Summary

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Patients aged ≥18 years.
With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
Who have received at least one of the doses of the study drugs.
In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
With at least two complete evaluations (baseline and final) of clinical variables.

Exclusion Criteria2

Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
Patients in whom more than 50% of the variables to be collected are missing in the data collection.